From left: Carsten Riether, Christian M. Schu’rch and Adrian F. Ochsenbein in the laboratory (photo: Susi Bu’rki, University Hospital Bern).
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells. Leukaemia stem cells: they have the ability to renew themselves and are resistant to most current, existing cancer therapies (chemotherapy, radiation, targeted medications) . Because the cells are responsible for the development of blood cancer, they also regulate the course of disease. The faster they multiply, the faster the illness progresses. Therefore, since 2009, the tumour immunology researchers PD Dr. sc. nat.
POUR LIRE CET ARTICLE, CRÉEZ VOTRE COMPTE
Et prolongez votre lecture, gratuitement et sans engagement.
